Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of PL 3100 vs Naproxen in Healthy Volunteers
NCT00966641Phase 2Completed
- Sponsor
- PLx Pharma Inc.
- Start
- Aug 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PL-3100 in pain and inflammation (2 arms), sponsored by PLx Pharma Inc. Primary endpoint: Area Under the Curve of Plasma Naproxen From 0 to t at 48 hours. Started Aug 2009; status: completed.
02
Drugs
PL-3100
03
Conditions
paininflammation
Beyond the preview
Go deeper on NCT00966641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00966641.